CHSY.F Stock Overview
An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
China Medical System Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.93 |
| 52 Week High | HK$0.93 |
| 52 Week Low | HK$0.93 |
| Beta | 0.83 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -38.69% |
| 33 Year Change | -61.22% |
| 5 Year Change | -4.05% |
| Change since IPO | 3.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHSY.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 0.7% |
| 1Y | -38.7% | 12.1% | 32.2% |
Return vs Industry: CHSY.F underperformed the US Pharmaceuticals industry which returned 18.5% over the past year.
Return vs Market: CHSY.F underperformed the US Market which returned 16.9% over the past year.
Price Volatility
| CHSY.F volatility | |
|---|---|
| CHSY.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHSY.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CHSY.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 5,701 | Kong Lam | web.cms.net.cn/zh/home/ |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis. The company also offers Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; ILUMETRI, a tildrakizumab injection to treat moderate-tosevere plaque psoriasis; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar.
China Medical System Holdings Limited Fundamentals Summary
| CHSY.F fundamental statistics | |
|---|---|
| Market cap | US$1.98b |
| Earnings (TTM) | US$330.82m |
| Revenue (TTM) | US$1.10b |
6.0x
P/E Ratio1.8x
P/S RatioIs CHSY.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHSY.F income statement (TTM) | |
|---|---|
| Revenue | CN¥8.01b |
| Cost of Revenue | CN¥1.94b |
| Gross Profit | CN¥6.08b |
| Other Expenses | CN¥3.68b |
| Earnings | CN¥2.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.98 |
| Gross Margin | 75.82% |
| Net Profit Margin | 29.96% |
| Debt/Equity Ratio | 8.3% |
How did CHSY.F perform over the long term?
See historical performance and comparison